SCHEMBL5437151

SCHEMBL5437151

Cc1ccc(-c2nc3ccncc3c(=O)o2)c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.51
F7 P08709 2/20 0.51
F3 P13726 2/20 0.51
F10 P00742 1/20 0.51
C1R P00736 8/20 0.47
KMT2A Q03164 4/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
PLG P00747 1/20 0.47
KLK1 P06870 1/20 0.47
PRSS1 P07477 1/20 0.47
C1S P09871 1/20 0.47
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ELANE P08246 2/20 0.46
KLK3 P07288 1/20 0.44
MEN1 O00255 3/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437118 0.84 F7 (0.56) F2F7F3F10C1R
SCHEMBL2537274 0.76 ELANE (0.73) F2C1RKMT2ANPC1RAB9A
SCHEMBL30914649 0.76 ELANE (0.73) F2C1RKMT2ANPC1RAB9A
SCHEMBL5426311 0.76 ELANE (0.50) F2F7F3F10C1R
SCHEMBL1964870 0.74 ELANE (0.61) F2F7F3F10KMT2A
SCHEMBL5433314 0.73 F7 (0.71) F2F7F3F10C1R
SCHEMBL913682 0.73 C1R (0.68) F2F7F3C1RKMT2A
SCHEMBL9475739 0.72 C1R (0.76) F2C1RKMT2ANPC1RAB9A
SCHEMBL17059024 0.71 RAB9A (0.65) F2C1RKMT2ANPC1RAB9A
SCHEMBL29371664 0.70 NPC1 (0.68) F2C1RKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold ASTRAZENECA AB (SE) 2007-09-27 US disclosed
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold ASTRAZENECA AB (SE) 2007-09-27 US disclosed
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold ASTRAZENECA AB (SE) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold OPRL1, OPRK1, P2RX3 F2 583/4885F7 2801/4885F3 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.